Erratum: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis (Blood (2017)130: 5 (597-605)DOI: 10.1182/blood-2017-03-771220)
Academic Article
Publication Date:
2020
abstract:
In “Acknowledgments” on page 604, support from the National Institutes of Health for Jeffrey A. Zonder (grant P30 CA022453) is not acknowledged. The error has been corrected in the online version of the article.
Iris type:
1.1 Articolo in rivista
List of contributors:
Sanchorawala, V; Palladini, G; Kukreti, V
Published in: